Aroa Biosurgery Launches New Product, Myriad Morcells™ - Offering Highly Conformable Tissue Regeneration in Wound Beds - Following Recent FDA Clearance
HIGHLIGHTS
Soft tissue regeneration company Aroa Biosurgery Limited has this week launched a new product named Myriad Morcells™, a morcellized (powder) format of Myriad Matrix™ that easily conforms to optimize contact with irregular wound beds.
It received U.S. FDA 510(k) clearance received for the product on 6 April 2021.
The morcellized format increases AROA ECM™ surface area to maximize delivery of important ECM proteins.
This clearance further builds on applications for the Myriad™ portfolio, following recent studies showing positive clinical outcomes for Myriad Matrix™’s use in surgical treatment of hidradenitis suppurativa, complex wounds and exposed vital structures.